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Abstract Protein drugs have attracted considerable atten-
tion as therapeutic agents due to their diversity and bio-
compatibility. However, hydrophilic proteins possess
difficulty in penetrating lipophilic cell membrane.
Although protein transduction domains (PTDs) have shown
effectiveness in protein delivery, the importance of selec-
tion and position of PTDs in recombinant protein vector
constructs has not been investigated. This study intends to
investigate the significance of PTD selection and position
for therapeutic protein delivery. Heat shock protein 27
(Hsp27) would be a therapeutic protein for the treatment of
ischemic heart diseases, but itself is insufficient to prevent
systemic degradation and overcoming biochemical barriers
during cellular transport. Among all PTD-Hsp27 fusion
proteins we cloned, Tat-Hsp27 fusion protein showed the
highest efficacy. Nona-arginine (9R) conjugation to the
N-terminal of Hsp27 (Hsp27-T) showed higher efficacy
than C-terminal. To test the synergistic effect of two PTDs,
Tat was inserted to the N-terminal of Hsp27-9R. Tat-
Hsp27-9R exhibited enhanced transduction efficiency and
significant improvement against oxidative stress and
apoptosis. PTD-Hsp27 fusion proteins have strong poten-
tial to be developed as therapeutic proteins for the treat-
ment of ischemic heart diseases and selection and position
of PTDs for improved efficacy of PTD-fusion proteins need
to be optimized considering protein’s nature, transduction
efficiency and stability.
Keywords Fusion proteins  Selection and position of
protein transduction domains (PTDs)  Heat shock protein
27  Hypoxia
Introduction
Since 2001, more than two hundred new FDA approvals of
protein drugs and peptides have emerged in mainstream
therapeutics. As a substitute for small molecules and gene
therapy, they represent a significant percentage of the
biopharmaceutical market (Arthanari et al. 2010; Walsh
2010). Protein drugs show highly diverse structures and
wide biological efficacies and thus have a considerable role
in both therapeutics and bio imaging. Protein drugs are
safer and more biocompatible than therapeutic gene
delivery (Tan et al. 2010). Hydrophilicity and large
molecular weight of protein drugs are core limiting factors
to their cellular level delivery (Carter 2011). Selective
permeability and lipophilic property of plasma membrane
prohibits protein drug delivery into cells. Additionally,
protein structure should not be broken for preventing their
dysfunction (Wang 2005). Peptide and protein drugs are
also prone to proteases and unspecific proteolysis. Hence,
efficient protein delivery through cell membrane could be
an arduous challenge.
Protein transduction domains (PTDs) conjointly known
as cell-penetrating peptides (CPPs) are a class of diverse
peptides, typically with 5–30 amino acids. In contrast to
many proteins, they can target intracellular proteins.
Importantly, PTDs can also incorporate other biomolecules
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such as proteins, DNA, antibodies and contrast agents into
cells, thus offering great potential as future therapeutics.
Among several alternative carrier-mediated delivery sys-
tems, use of CPPs as a carrier for cellular delivery is taken
into account as one of the best strategy (Snyder and Dowdy
2004; Deshayes et al. 2005; Gupta et al. 2005). PTDs can
also efficiently transport cargos which are several times
greater in molecular weights than their own and are effi-
cient for a large range of cell types (Van den Berg and
Dowdy 2011).
Trans-activator of transcription (Tat: GRKKRRQRR
RPQ), first discovered PTD, and poly-arginine represents
the cationic class of PTDs. HIV-1 Tat has showed effective
transduction capability for various cargos (Lim et al. 2010;
Won et al. 2010; Arthanari et al. 2010; Zhang et al. 2012).
It consists of positively charged transduction through
negatively charged phospholipid on cell membrane. Since
then, positively charged amino acids are highlighted as a
key factor for transduction capacity. Studies on poly-argi-
nine (from R3 to R12) have evidenced that octa-arginine
(R8) is minimal sequence for cellular uptake, and by
increasing number of arginine, cellular uptake can be
increased. Later it was shown that octa-arginine (8R) and
nona-arginine (9R) showed more transduction as compared
to undeca-arginine (11R) and dodeca-arginine (12R).
Studies suggest that for efficient cellular internalization at
least eight positive charges of cationic PTDs are needed.
Among cationic PTDs, charged residues have a more cru-
cial role in cellular uptake.
Even after intense research on PTDs, the exact mecha-
nism of PTDs internalization into cytoplasm of these PTDs
remains under intense investigation and is not fully
understood. Energy-independent pathways, direct trans-
duction by hydrophobic interaction between cell membrane
and hydrophobic amino acids of Tat (Ziegler 2008; Sch-
midt et al. 2010; Mishra et al. 2011) and endocytic pathway
are suggestions still open to debate. It seems clear that out
of all, two types of mechanisms coexist, which dissent
dramatically in terms of efficacy. In addition to PTDs
direct transduction through electrostatic interactions on
lipid bilayer (Herbig et al. 2005), an energy-dependent
primary endocytic pathway is responsible for intracellular
transport (Wadia et al. 2004). Whereas a Tat peptide shows
various translocation mechanisms according to their cargo,
9R mainly transports a cargo by endocytosis mechanism
(Takeuchi et al. 2006). It is now evident that various PTDs
and PTDs–cargos can enter cells by different mechanisms
(Duchardt et al. 2007), therefore, significance of PTD
selection and position should be emphasized and consid-
ered an important factor for effective penetration of
protein.
In this study, we intend to prove significance of PTD
selection by using PTD-conjugated heat shock protein 27
(Hsp27) fusion proteins. Hsp27 is a chaperone with a
molecular weight of 27 kDa. It inhibits apoptosis against
hypoxia in cells by interacting directly with caspase acti-
vation components (Tan et al. 2009), especially when
linked with PTDs, it showed significant effects against
hypoxia as shown in Fig. 1 (Kwon et al. 2007; Liu et al.
2014). 9R was conjugated to C-terminus and N-terminus of
Hsp27-protein to compare effect of PTDs by their loca-
tions. Tat conjugated to Hsp27 was used as a positive
control (Tan et al. 2009). As 9R-Hsp27 showed better
results than Hsp27-9R, Tat was conjugated at N-terminal of
Hsp27-9R to observe improvement in Hsp27-9R. After
anti-apoptotic efficacy comparison, it was concluded that
N-terminal conjugated PTD-Hsp27 fusion proteins have
more protective effects than C-terminal.
Materials and methods
Materials
H9c2 cells (Rat cardio myoblast) were obtained from a
Korean cell line bank (Seoul, Korea). High glucose Dul-
becco’s Modified Eagle’s Medium (DMEM) and fetal
bovine serum (FBS) were purchased from WelGENE
(Seoul, Korea). Cy5-Intracellular nucleic acid localization
kit was obtained from Mirus Bio Corporation (Madison,
USA). DC protein assay kit and Bovine Serum Albumin
(BSA) standard were purchased from Bio-Rad Laboratories
(Hercules, CA). Dialysis Membrane (MWCO: 12-14,000)
was obtained from Spectrum Laboratories (Richmond,
CA).
Cloning
To construct PTD-Hsp27 fusion proteins, Hsp27 a cDNA
sequence from PAcGFP1-N, obtained from Invitrogen (La
Jolla, CA), was inserted into pET28a bacterial expression
vector. First, 9R (CGA CGT CGC CGG CGT CGA CGT
CGA CGG) or Tat (p47–57; TAT GGC AGG AAG AAG
CGG AGA CAG CGA CGA CGA) peptide were cloned
into pET28a vector to construct pET28a-9R or pET28a-Tat
vectors with poly-histidine (HHHHHH) affinity tag at C-
terminal. Then, to clone Hsp27 into pET28a-9R or
pET28a-Tat vectors, Hsp27 cDNA was amplified and
cloned into pET28a-9R and pET28a-Tat vectors between
each restriction enzyme sites. Finally, pET28a-T-Hsp27,
pET28a-9R-Hsp27, pET28a-Hsp27-9R, and pET28a-T-
Hsp27-9R vectors were verified by DNA sequencing. All
plasmid constructs for PTD-conjugated proteins were
synthesized and analyzed by Cosmo Genetech (Seoul,
Korea).
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Expression and purification of plasmid constructs
for PTD-conjugated Hsp27 fusion proteins
Plasmid constructs for PTD-conjugated proteins were
transformed to Escherichia coli BL21 strain, obtained from
Strata gene (La Jolla, CA). Bacteria were cultured in LB
medium with 50 lg/ml kanamycin at 37 C with shaking
for 4 h until the OD600 value reached 0.6–0.8. Protein
expression was stimulated by adding 1 mM isopropyl b-D-
1-thiogalactopyranoside and shaking for 16 h at 26 C.
Cell pellets were collected by centrifugation at 4,800 9 g-
force for 10 min and cells were re-suspended by using lysis
buffer with 100 mM phenyl-methyl-sulfonyl-fluoride.
After re-suspension, cells were sonicated for 25 s each time
and then cell debris was separated from proteins by cen-
trifugation at 27,500 9 g-force for 25 min. Separated
proteins were then filtered through 0.45 lm filter. With
elution buffer, proteins were purified by immobilized metal
affinity chromatography with FPLC using Ni–NTA resin
column. Purified proteins were solubilized in elution buf-
fer, and impurities were removed by using dialysis mem-
brane (MWCO: 12-14,000), in phosphate buffered saline
(PBS) buffer. Purified fusion proteins were aliquoted
respectively and stored at 4 or -70 C.
Immunoblotting
PTD-conjugated fusion proteins were identified by
immunoblotting. After electrophoresis on 15 % SDS-
polyacrylamide gel, fusion proteins were transferred to
PVDF membrane overnight at 4 C following blockage
with 5 % skim milk. Transferred proteins were then treated
with primary His-Tag polyclonal antibody, purchased from
Cell Signaling (Danvers, MA), over-night at 4 C followed
by treatment with secondary anti-rabbit HRP-linked IgG
for 2 h at 4 C. Membranes were visualized with ECL Plus
solution.
Cell culture
H9c2 cells were cultured in DMEM (D-glucose: 4,500 mg/
l, L-glutamine, sodium pyruvate: 110 mg/l, sodium bicar-
bonate) high glucose containing penicillin (100 U/ml)
streptomycin (100 mg/ml) and 10 % FBS. Cells were
maintained at 37 C with 5 % CO2.
Cytotoxicity assay
MTT assay was performed to measure cytotoxicity of PTD-
conjugated fusion proteins. H9c2 cells were seeded in 96
well plate for 24 h at 37 C. Cells were then treated with
1–10 lM PTD-Hsp27 fusion proteins for 4 h. To check cell
viability, MTT reagent was added to cells following
incubation at 37 C for 2 h. The absorbance was measured
by an ELISA plate reader at 570 nm. Cytotoxicity assay
was repeated three times with four replicates.
Immunofluorescence assay
To observe intracellular uptake, H9c2 cells were seeded
onto cover glass for 24 h. PTD-conjugated fusion proteins
were labeled with cy5 as described by manufacturer. Cells
were treated with PTD-conjugated fusion proteins with
5 lM PTD-Hsp27 concentration for 24 h. Cells were then
washed with ice-cold PBS and counterstained with DAPI.
To detect intracellular transduction, cells were immediately
fixed at 4 C with 3.7 % formaldehyde. Transduction of
PTD-conjugated fusion proteins was observed by a con-
focal microscope (Carl Zeiss; Jena GmbH, Germany).
Flow cytometry analysis
Flow cytometry analysis was performed to confirm PTD-
Hsp27 fusion protein’s transfection. H9c2 cells were seeded
in six well plates for 24 h. PTD-Hsp27 fusion proteins were
labeled with alexa488 according to manufacturer instruc-
tions. 5 lM of labelled fusion proteins were added and
incubated for 24 h. Cells were collected by trypsinization
and centrifugation. Single cell suspension was prepared in
FACS buffer (2 % FBS, 0.02 % sodium azide/PBS). Inter-
nalization of PTD-Hsp27 fusion proteins was evaluated by a
BD FACS Caliber flow cytometer (San Jose, CA).
Hypoxia induction
In order to test anti-apoptotic effects of PTD-Hsp27 fusion
proteins, H9c2 cells were exposed to apoptotic condition
by treatment with sodium arsenide, NaAsO2. The 50 %
inhibitory concentration of cell viability (IC50) was
screened at NaAsO2 concentrations below 15 lM. Cells
were incubated for 24 h at 37 C under 95 % N2, and 5 %
CO2 in a hypoxia chamber. Cell viability was measured by
MTT assay.
Apoptosis assay
H9c2 cells were seeded in 96 well plates and treated with
10 lM NaAsO2 and 5 lM of Hsp27 and PTD-conjugated
Hsp27 fusion proteins. Anti-apoptotic effects of PTD-
Hsp27 fusion proteins were measured by MTT assay fol-
lowing 24 h incubation with proteins.
Statistical analysis
All data are represented as mean ± SD (standard devia-
tion) (n = 3). Statistical analysis was performed with
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Student’s t test. P values less than 0.05 were considered
statistically significant.
Results
Expression and purification of PTD-conjugated
Hsp27 fusion proteins
The pET28a vector was used to construct pET28a-Tat and
pET28a-9R vectors with C-terminal poly histidine
(69 His) affinity tag. Hsp27 genes were cloned into
pET28a-Tat and pET28a-9R vectors. Vector designs of
PTD-Hsp27 fusion proteins and their nucleotide sequences
were confirmed by sequence analysis. Tat and 9R were
cloned to C-terminus or N-terminus of Hsp27. Vector
constructs of Hsp27 recombinant proteins are shown in
Fig. 2a.
PTD-conjugated fusion proteins were collected from
BL21 E. coli lysates and purified by nickel affinity chro-
matography using a Ni–NTA resin column with FPLC. Ni–
NTA resin column in FPLC was used to capture and purify
69 His tag-labeled proteins. SDS-PAGE was used to
identify purified PTD-Hsp27 fusion proteins as shown in
Fig. 2b. After electrophoresis on 15 % SDS-polyacry-
lamide gel, fusion proteins were transferred to PVDF
membrane overnight at 4 C and then treated with His-tag
polyclonal antibody and secondary anti-rabbit HRP-linked
IgG. Western blot results for PTD-Hsp27 are shown in
Fig. 2c.
In vitro cytotoxicity assay
The cytotoxicity of all PTD-Hsp27 recombinant fusion
proteins in H9c2 cells was tested in dose dependent mode
from 1 to 10 lM. Cells were treated with 1, 3, 5, 7 and
10 lM PTD-Hsp27 purified fusion proteins for 24 h. MTT
assay was used to determine cell viability. As shown in
Fig. 3, no significant cytotoxicity was observed in any of
the PTD-Hsp27 fusion proteins treated groups within the
assigned dose-range of 1–10 lM. For further experiments,
the protein concentration was fixed at 5 lM. These results
suggest that PTDs such as 9R and Tat could be used as safe
therapeutic protein carriers with minimum toxicity in
mammalian cells regardless from their site of attachment
with therapeutic protein Hsp27.
Intracellular transduction of PTD-Hsp27 fusion
proteins
To function against hypoxia, Hsp27 should be located in
the cytosol. However, it is difficult to penetrate cell
Fig. 1 Schematic illustration of
transduction of PTD-Hsp27
fusion proteins and their
therapeutic effects on apoptosis
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membranes for Hsp27 itself due to its hydrophilic and
macromolecular characteristics. The recombinant fusions
of PTD with Hsp27 were considered to enrich the trans-
duction efficiency of Hsp27. Although transduction
mechanisms of PTD fusion proteins are still controversial,
the high transduction efficiency of T- and 9R-Hsp27 fusion
proteins was expected. In order to visualize internalization
and retention of PTD-Hsp27 fusion proteins in H9c2 cells,
confocal laser scanning microscopy (CLSM)was used and
intracellular trafficking of proteins was observed after 24 h
of treatment.
PTD-Hsp27 fusion proteins were conjugated by Cy5,
following counter-staining with DAPI. As shown in
Fig. 4a, florescence of Cy5 in T-Hsp27 group was dis-
persed more widely in cytoplasm than other groups (H,
9RH, H9R, TH9R), in H9c2 cells. In case of 9R-Hsp27,
Hsp27-9R and T-Hsp27-9R groups, less Cy5 florescence
intensities were detected in cytoplasm. Among 9R-Hsp27
and Hsp27-9R fusion proteins, 9R-Hsp27 showed less
florescence. Florescence intensities were quantified by
Image J software.
Flow cytometry analysis of PTD-Hsp27 fusion
proteins
For further comparison of PTD-Hsp27 fusion protein’s
transfection efficiency, flow cytometry was performed and
mean fluorescence intensity (MFI) from triplicate for each
group was recorded. PTD-Hsp27 fusion proteins were
labeled with alexa488 according to manufacturer instruc-
tions and excessive dye was removed by dialysis in PBS.
Cells were treated with PTD-Hsp27 fusion proteins at
5 lM concentration and incubated at 37 C for 24 h. After
incubation, cells were collected by trypsinization followed
by washing and centrifugation. Single cell suspension was
prepared in FACS buffer (2 % FBS, 0.02 % sodium azide/
PBS). Internalization of PTD-Hsp27 fusion proteins was
evaluated by a FACS Canto II Caliber flow cytometer (BD
Fig. 2 PTD-Hsp27 fusion
proteins purification and
expression. a Schematic
structures of vector constructs
b identification of PTD-Hsp27
fusion proteins by SDS-PAGE
and c western blot. H Heat





Fig. 3 In vitro cytotoxicity of
PTD-Hsp27 fusion proteins in
H9c2 cells
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Franklin Lakes, NJ) and data was analyzed by Cell Quest
Pro software. Figure 5a represents that T-Hsp27 fusion
protein retains 90.4 % transfection efficiency significantly
higher than 9R-Hsp27 (43.6 %), Hsp27-9R (29.7 %) and
T-Hsp27-9R (53.9 %). This data confirms that Tat provides
better transfection efficiency for Hsp27 than 9R. As shown
in Fig. 5b), the MFI values were also measured with
transfection of Alexa 488-conjugated PTD-Hsp27 fusion
proteins. The mean fluorescence intensity of T-Hsp27 was
52.7 and relative values of 9R-Hsp27, Hsp27-9R and
T-Hsp27-9R groups were about 26.8, 13.9 and 32.3,
respectively.
Anti-apoptotic effect of PTD-Hsp27 fusion proteins
in hypoxia condition
Anti-apoptotic effects of PTD-Hsp27 fusion proteins in
hypoxic conditions were studied to determine the impact of
Hsp27 as protective agent. Anti-apoptotic effects of PTD-
Hsp27 were observed by measuring cell viability of H9c2
cells in hypoxic conditions.
Sodium arsenite (NaAsO2), an appropriate chemical
stressor through the generation of reactive oxygen species
(ROS), (Watson et al. 1996) was used to generate hypoxic
state of H9c2 cells. Studies also show that NaAsO2 can
induce a dose-dependent increase of ROS in cultured
human cells. Therefore to optimize IC50, MTT assay was
performed with various concentration of NaAsO2. At
10 lM NaAsO2 concentration, 51.3 % cell viability was
observed, hence, 10 lM NaAsO2 was used in further
experiments to generate hypoxic environment.
To evaluate the effects of PTD-Hspp27 fusion proteins
in hypoxic condition, H9c2 cells were treated with 5 lM of
PTD-Hsp27 fusion proteins for 24 h. Cell viability in
T-Hsp27 treated cells increased about *25 % while there
was no significant effect in Hsp27 treated cells. Cell via-
bility in 9R-Hsp27, Hsp27-9R and T-Hsp27-9R groups
increased about*20, 17 and 15 %, respectively (Fig. 6b).
In the case of 9R-Hsp27, Hsp27-9R and T-Hsp27-9R, the
protective effects were much higher than with just Hsp27,
indicating that Hsp27 itself could not be transduced effi-
ciently into cells. These results indicate that transduction of
Hsp27 into cells is essential for the protection of cells
against hypoxia and that Hsp27 is an anti-hypoxic protein.
Discussion
Most intractable in vivo barriers for protein drug candi-
dates are the immunological responses caused by the
recognition of the protein as a foreign antigen. Key factors
causing immunogenicity are impurities and aggregations,
further resulting in loss of protein efficacy. To cope up with
the immunogenicity issue, protein drugs need to be soluble
and non-aggregated. Although the fusion protein drugs in
market are generally safe and effective, the expensive cost
of drugs has become another issue for chronic patients. In
order to scale back the price and side effects, the drug
candidate should be potent to keep the dose minimum.
Fig. 4 Intracellular uptake of PTD-Hsp27 fusion proteins. Cells were incubated with cy5 conjugated PTD-Hsp27 fusion proteins for 24 h.
CLSM images were merged with PTD-conjugated fusion proteins following counterstaining with DAPI
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Furthermore, specific targeting of protein drug into disease
sites should be achieved to minimize side effects and
maximize efficacy.
PTDs are widely-tested carriers for DNA, RNA and
proteins intracellular delivery (Del Gaizo and Payne 2003;
Kaplan et al. 2005; Shokolenko et al. 2005). Here we
prepared PTD-Hsp27 fusion proteins by cloning and fusing
Hsp27 plasmid with PTDs to inhibit apoptosis in hypoxic
conditions. Hsp27, a heat-shock protein, has crucial roles in
many cellular processes including apoptosis, cellular dif-
ferentiation and cytoskeleton dynamics. With the assis-
tance of protein transduction domains, all of PTD-Hsp27
recombinant fusion proteins efficiently penetrated into
cardiomyocytes. Amphipathic property and charge
Fig. 5 Flow cytometry analysis of PTD-Hsp27 fusion proteins. H9c2 cells were transfected with alexa488 labelled Hsp27 and PTD-Hsp27
fusion proteins, (T-Hsp27, 9R-Hsp27, Hsp27-9R and T-Hsp27-9R). The fluorescence intensity of Alexa488 was measured after 24 h by FACS
analysis
Fig. 6 In vitro anti-apoptotic effects of PTD-conjugated fusion proteins. a IC50 was measured with different conc. of NaAsO2. b Cell viability
was measured to check anti-apoptotic activity by 5 lM PTD-Hsp27
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distribution are considered to be two important factors for
cellular transduction of PTDs as the cellular transduction
mechanism of and cationic property of PTDs alone is not
absolute factor determining transduction efficiency of PTD
because 9R containing more cationic amino acids without
hydrophobic amino acids than Tat demonstrated less
effective delivery of Hsp27 into cells. Taken together it can
be observed that 9R conjugated with N-terminal of Hsp27
and T-Hsp27-9R can show more therapeutic efficacy than
9R conjugated to C-terminal of Hsp27 as they less aggre-
gated and are more susceptible to produce therapeutic
effects. Both MFI and florescence percentage values con-
clude that N-terminal conjugation improve transduction of
PTD-Hsp27 fusion proteins and Hsp27 itself doesn’t have
enough transduction efficiency to produce therapeutic
effects. These results also endorse the previous results that
N-terminal conjugated PTD-Hsp27, protected more cells
against apoptosis than C-terminal conjugated PTD-HSp27,
by interfering with apoptosis extrinsic pathway. T-Hsp27
showed the best transduction efficiency of all recombinant
Hsp27 fused proteins with 9R and Tat combinations tested.
N-terminal was proven to be important domain for the
transduction of Hsp27 as Hsp27 conjugated with PTD at
N-terminal showed better efficiency than Hsp27 conjugated
with PTD at C-terminal. Moreover, cationic property of
PTD alone is not a single parameter determining trans-
duction efficiency of PTD followed by therapeutic efficacy
as 9R showed less effective delivery of Hsp27 into cells
than Tat even though it has more cationic amino acids than
Tat.
The selection and position of PTDs for improved effi-
cacy of PTD fusion proteins need to be optimized con-
sidering protein’s nature, transduction efficiency, stability
and efficacy. PTD-Hsp27 fusion proteins, particularly
T-Hsp27 fusion proteins, may be useful therapeutic pro-
teins leading to efficient intracellular delivery of Hsp27
into hypoxic cells. In vivo efficacy of PTD-Hsp27 fusion
proteins need to be evaluated in hypoxic diseases.
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